Pharma deals in China face heightened IP risk under U.S. BIOSECURE Act

Pharma companies are increasing licensing activity in China, but experts say patent attorneys must now factor in the geopolitical implications of the BIOSECURE Act.

The legislation seeks to compile a list of Chinese manufacturers considered security threats, reflecting worries about supply‑chain vulnerabilities that surfaced during the COVID pandemic.

Intellectual‑property lawyers note that China has a documented pattern of leveraging its supply‑chain position, and the new rules could add complexity to negotiations and raise the likelihood of disputes.

Companies are advised to involve seasoned IP counsel when structuring Chinese biotech deals to ensure compliance with the emerging regulatory framework.